Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).
Agresti R, Martelli G, Sandri M, Tagliabue E, Carcangiu ML, Maugeri I, Pellitteri C, Ferraris C, Capri G, Moliterni A, Bianchi G, Mariani G, Trecate G, Lozza L, Langer M, Rampa M, Gennaro M, Greco M, Menard S, Pierotti MA. Agresti R, et al. Among authors: carcangiu ml. Cancer. 2014 Mar 15;120(6):885-93. doi: 10.1002/cncr.28499. Epub 2013 Dec 5. Cancer. 2014. PMID: 24323615 Free article. Clinical Trial.
Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study.
Martelli G, Miceli R, Folli S, Guzzetti E, Chifu C, Maugeri I, Ferranti C, Bianchi G, Capri G, Carcangiu ML, Paolini B, Agresti R, Ferraris C, Piromalli D, Greco M. Martelli G, et al. Among authors: carcangiu ml. Eur J Surg Oncol. 2017 Nov;43(11):2012-2020. doi: 10.1016/j.ejso.2017.07.023. Epub 2017 Aug 10. Eur J Surg Oncol. 2017. PMID: 28912071
Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, Alessi A, Pellitteri C, Maccauro M, Maugeri I, Barbara P, Rampa M, Moscaroli A, Ferraris C, Carcangiu ML, Bianchi G, Greco M, Bombardieri E. Agresti R, et al. Among authors: carcangiu ml. Breast. 2014 Aug;23(4):334-40. doi: 10.1016/j.breast.2014.01.001. Epub 2014 Jan 31. Breast. 2014. PMID: 24485802 Free article.
Management of breast cancer after Hodgkin's lymphoma and paediatric cancer.
Terenziani M, Massimino M, Magazzù D, Gandola L, Capri G, Carcangiu ML, Catania S, Di Russo A, Gennaro M, Meazza C, Podda M, Schiavello E, Valagussa P. Terenziani M, et al. Among authors: carcangiu ml. Eur J Cancer. 2015 Sep;51(13):1667-74. doi: 10.1016/j.ejca.2015.05.024. Epub 2015 Jun 16. Eur J Cancer. 2015. PMID: 26092639
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Triulzi T, et al. Among authors: carcangiu ml. Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405. Oncotarget. 2015. PMID: 26334217 Free PMC article.
Radiation effects on development of HER2-positive breast carcinomas.
Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, Triulzi T, Gasparini P, Camerini T, Sozzi G, Fossati-Bellani F, Ménard S, Tagliabue E. Castiglioni F, et al. Among authors: carcangiu ml. Clin Cancer Res. 2007 Jan 1;13(1):46-51. doi: 10.1158/1078-0432.CCR-06-1490. Clin Cancer Res. 2007. PMID: 17200337
188 results